By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Wilson Therapeutics 

  Stockholm    Sweden
Phone: n/a Fax: n/a



Company News
Wilson Therapeutics Presents Data On Decuprate (WTX101) From Ongoing Phase 2 Study At The International Liver Congress 2016 4/14/2016 10:48:09 AM
Wilson Therapeutics Appoints Anders Martin-Lof As Chief Financial Officer 11/3/2015 6:56:37 AM
Wilson Therapeutics Appoints Andrew Kay As Chairman 10/20/2015 11:12:52 AM
Wilson Therapeutics Announces The Appointment Of Dr. Carl Bjartmar As Chief Medical Officer 7/22/2015 9:06:37 AM
Wilson Therapeutics Appoints Hans Schikan To Its Board Of Directors 7/2/2015 6:27:20 AM
Wilson Therapeutics Announces Support Of The BIG WOW To Raise Awareness Of Wilson's Disease 6/17/2015 8:54:25 AM
Wilson Therapeutics To Present As A "Next Wave" Company During BioEquity 2015 Conference In Vienna On May 19th 5/6/2015 11:13:48 AM
Wilson Therapeutics Announces Presentation Of WTX101-201 Phase 2 Study At The EASL 50th International Liver Congress 2015 4/16/2015 7:43:24 AM
Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 11/17/2014 10:10:55 AM
Wilson Therapeutics Bags $40 Million To Advance Late Stage Development Program For Wilson's Disease 4/16/2014 6:19:58 AM